Drug profile · INN
sirolimus
RAPAMUNE
sirolimus (RAPAMUNE) is a fk506-binding protein 1a inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — sirolimus
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- TOPICAL
- Patents
- 0
- Programs
- 20
- Data quality
- 0.89
Quick answer
sirolimus (RAPAMUNE) is a fk506-binding protein 1a inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
FK506-binding protein 1A inhibitor
Primary target: Peptidyl-prolyl cis-trans isomerase FKBP1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sirolimus?
sirolimus (RAPAMUNE) is a fk506-binding protein 1a inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for sirolimus?
RAPAMUNE is a marketed brand name for sirolimus. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sirolimus?
sirolimus has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.